Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
'We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We look forward to reporting initial data from our two ongoing Phase 1 clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets.'
Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% common equity position in DCx (including certain dilution protection rights) and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low-single digit tiered sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees. Repare has the right to appoint one nominee to the board of directors of DCx. In connection with the transaction, Repare out-licensed its clinically-validated SNIPRx platform and its early discovery-stage SNIPRx-surf and STEP 2 platforms, along with other intellectual property. The SNIPRx-surf platform identifies cell surface targets based on gene expression and protein features in tumors or cancer models, including by clinically relevant biomarkers and machine learning algorithm. The STEP 2 platform is a chemogenomic discovery platform, which uses CRISPR-enabled genetic screens with small molecule inhibitors to identify clinically relevant genetic lesions that are sensitive to small molecule inhibitors.
About Repare Therapeutics Inc.
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare has utilized its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Repare's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
About DCx Biotherapeutics Corporation
DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precisiono0 antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit www.dcxbio.com to learn more.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: Repare's out-license of its discovery platform to DCx; the risk that Repare may not realize the potential benefits of the transaction with DCx; Repare's ability to drive cost reductions while maintaining an economic interest in its assets; the timing, progress and results of Repare's two ongoing Phase 1 clinical trials; and the receipt of milestone payments and royalties under the out-license agreement. These forward-looking statements are based on Repare's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Repare's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and changes in tariffs and trade policies, on Repare's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Repare's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Repare's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in Repare's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ("AMF") on March 3, 2025. Repare expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure?
CRISPR Therapeutics AG recently reported its second quarter 2025 earnings, posting revenue of US$892,000, up from US$517,000 a year ago, but recording a net loss of US$208.55 million, up from US$126.41 million in the same period last year. Despite modest revenue gains, the significantly wider loss per share suggests rising costs or investment pressures are impacting the company's financial trajectory. We'll explore how the widening net loss and higher reported expenses could reshape CRISPR Therapeutics' investment narrative going forward. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. What Is CRISPR Therapeutics' Investment Narrative? To be a shareholder in CRISPR Therapeutics, you need conviction in the promise of gene-editing breakthroughs and the company's ability to translate pipeline progress into eventual commercial returns. The latest earnings report, though, spotlights a widening net loss and sharply higher operating expenses. While ongoing clinical trials and recent index inclusions remain key near-term catalysts, the size of the reported quarterly loss raises questions around cash burn and the timeline to profitability. This new financial data could shift expectations for the pace of hiring, R&D investment, or the need for additional funding, potentially affecting sentiment around CRISPR's risk profile. On balance, the recent news does not appear to instantly derail the main product development catalysts investors were tracking, but it sharpens focus on the sustainability of current spending levels and paths to revenue growth in a high-cost environment. But with losses widening, funding needs are something every investor should watch closely. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be. Exploring Other Perspectives Eighteen members of the Simply Wall St Community offer fair value estimates for CRISPR Therapeutics, ranging from US$14.57 to US$150.97 per share. As these forecasts reveal, opinions differ widely on the company's trajectory, particularly given growing expenses flagged in the latest earnings. Exploring several alternative viewpoints can help you understand the breadth of market expectations. Explore 18 other fair value estimates on CRISPR Therapeutics - why the stock might be worth less than half the current price! Build Your Own CRISPR Therapeutics Narrative Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance. Ready For A Different Approach? Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped: Find companies with promising cash flow potential yet trading below their fair value. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
an hour ago
- New York Post
Air Canada cabin staff go on strike, grounding hundreds of flights
Air Canada's unionized flight attendants walked off the job early on Saturday morning after contract talks with the country's largest carrier stalled, in a move that could disrupt travel plans for more than 100,000 passengers. The union representing more than 10,000 Air Canada flight attendants confirmed the action in a social media post at around 1:00 a.m. in the first strike by cabin crew since 1985. Attendants are currently paid when the plane is moving and the union was seeking to also be compensated for time on the ground between flights and helping passengers board. 5 Air Canada union activists interrupt a press conference by airline executives on Aug. 14, 2025. REUTERS Montreal-based Air Canada, which is expected to respond quickly by locking out the workers, has said it anticipated canceling 500 flights by the end of Friday during the busy summer travel season. It expected around 100,000 people to be affected on Friday alone. Flight attendants are likely on Saturday to picket at major Canadian airports, where passengers were already trying to secure new bookings earlier in the week, as the carrier gradually wound down operations. Passenger Freddy Ramos, 24, said on Friday at Canada's largest airport in Toronto that his earlier flight was canceled due to the labor dispute and he had been rebooked by Air Canada to a different destination. 'Probably 10 minutes prior to boarding, our gate got changed and then it was canceled and then it was delayed and then it was canceled again,' he said. 5 Air Canada planes sit on the tarmac at Pearson International Airport in Toronto, Canada on Aug. 14, 2025. Getty Images 5 Air Canada flight attendants walk through the terminal of Montreal-Pierre Elliott Trudeau International Airport in Dorval, Quebec on Aug. 15, 2025. AP Air Canada and its low-cost affiliate Air Canada Rouge normally carry about 130,000 customers a day. Air Canada is also the foreign carrier with the largest number of flights to the US. While the dispute has generated support from passengers on social media for the flight attendants, Canadian businesses reeling from a trade dispute with the United States urged the federal government to impose binding arbitration on both sides, which would end the strike. Air Canada has asked the minority Liberal government of Prime Minister Mark Carney to order both sides into binding arbitration although the Canadian Union of Public Employees, which represents the attendants, said it opposed the move. The Canada Labour Code gives Jobs Minister Patty Hajdu the right to ask the country's Industrial Relations Board to impose binding arbitration in the interests of protecting the economy. Hajdu has repeatedly urged the two sides, which are not bargaining, to return to the table. The union has said Air Canada offered to begin compensating flight attendants for some work that is now unpaid but only at 50% of their hourly rate. 5 Flight attendants are likely on Saturday to picket at major Canadian airports, where passengers were already trying to secure new bookings earlier in the week, as the carrier gradually wound down operations. AP 5 A passenger looks at the canceled and delayed Air Canada flights on a departure board at Montreal-Pierre Elliott Trudeau International Airport. AP The carrier had offered a 38% increase in total compensation for flight attendants over four years, with a 25% raise in the first year, which the union said was insufficient. In a note to clients on Friday, analysts at financial services firm TD Cowen urged the carrier to 'extend an olive branch to end the impasse,' adding that investors are worried that any cost savings on labor are outweighed by lost earnings in the airline's most important quarter. 'We think it would be best for AC to achieve labor peace,' the note said. 'Not budging on negotiations risks being a Pyrrhic victory.'
NBC News
an hour ago
- NBC News
Air Canada suspends all operations as flight attendants go on strike
TORONTO — Air Canada suspended all operations as more than 10,000 Air Canada flight attendants went on strike early Saturday after a deadline to reach a deal passed, leaving travelers around the world stranded and scrambling during the peak summer travel season. Canadian Union of Public Employees spokesman Hugh Pouliot confirmed the strike has started after no deal was reached, and the airline said shortly after that it would halt operations. A bitter contract fight between Canada's largest airline and the union representing 10,000 of its flight attendants escalated Friday as the union turned down the airline's request to enter into government-directed arbitration, which would eliminate its right to strike and allow a third-party mediator to decide the terms of a new contract. Flight attendants walk off the job Flight attendants walked off the job around 1 a.m. ET on Saturday. Around the same time, Air Canada said it would begin locking flight attendants out of airports. Federal Jobs Minister Patty Hajdu met with both the airline and union on Friday night and urged them to work harder to them to reach a deal 'once and for all.' 'It is unacceptable that such little progress has been made. Canadians are counting on both parties to put forward their best efforts,' Hajdu said in a statement posted on social media. Pouliot, the spokesman for the union, earlier said the union had a meeting with Hajdu and representatives from Air Canada earlier Friday evening. 'CUPE has engaged with the mediator to relay our willingness to continue bargaining — despite the fact that Air Canada has not countered our last two offers since Tuesday,' he said in a email. 'We're here to bargain a deal, not to go on strike.' Travelers are in limbo A complete shutdown will impact about 130,000 people a day, and some 25,000 Canadians a day may be stranded abroad. Air Canada operates around 700 flights per day. Montreal resident Alex Laroche, 21, and his girlfriend had been saving since Christmas for their European vacation. Now their $8,000 trip with nonrefundable lodging is on the line as they wait to hear from Air Canada about the fate of their Saturday night flight to Nice, France. How long the airline's planes will be grounded remains to be seen, but Air Canada Chief Operating Officer Mark Nasr has said it could take up to a week to fully restart operations once a tentative deal is reached. Passengers whose travel is impacted will be eligible to request a full refund on the airline's website or mobile app, according to Air Canada. The airline said it would also offer alternative travel options through other Canadian and foreign airlines when possible. But it warned that it could not guarantee immediate rebooking because flights on other airlines are already full 'due to the summer travel peak.' Laroche said he considered booking new flights with a different carrier, but he said most of them are nearly full and cost more than double the $3,000 they paid for their original tickets. 'At this point, it's just a waiting game,' he said. Laroche said he was initially upset over the union's decision to go on strike, but that he had a change of heart after reading about the key issues at the center of the contract negotiations, including the issue of wages. 'Their wage is barely livable,' Laroche said. Sides say they're far apart on pay Air Canada and the Canadian Union of Public Employees have been in contract talks for about eight months, but they have yet to reach a tentative deal. Both sides say they remain far apart on the issue of pay and the unpaid work flight attendants do when planes aren't in the air. The airline's latest offer included a 38% increase in total compensation, including benefits and pensions over four years, that it said 'would have made our flight attendants the best compensated in Canada.' But the union pushed back, saying the proposed 8% raise in the first year didn't go far enough because of inflation.
